5'-nucleotidases, nucleosides and their distribution in the brain: Pathological and therapeutic implications

Current Medicinal Chemistry

Volumn 20, Issue 34, 2013, Pages 4217-4240

  Kovács, Zsolt ^a   Dobolyi, Árpád ^b   Kékesi, Katalin A ^c   Juhász, Gábor ^c  

^a UNIVERSITY OF WEST HUNGARY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

5' nucleotidases; Human brain diseases; Nucleoside system regionality; Therapy

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE KINASE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ALLOPURINOL; CLOZAPINE; DIPYRIDAMOLE; ECTO 5' NUCLEOTIDASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 3; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 4; GUANINE DEAMINASE; GUANOSINE; GW 493838; INOSINE; ISTRADEFYLLINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; NUCLEOSIDE TRANSPORTER; NUCLEOSIDE TRIPHOSPHATE; PRELADENANT; PROPENTOFYLLINE; PURINE NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINE NUCLEOSIDE; PYRIMIDINE NUCLEOTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE;

ALCOHOLISM; ALZHEIMER DISEASE; ARTICLE; BRAIN DISEASE; BRAIN LEVEL; BRAIN REGION; CELL ADHESION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE; ENZYME ACTIVITY; ENZYME LOCALIZATION; EPILEPSY; HUMAN; HUNTINGTON CHOREA; MANIA; MEMORY DISORDER; MIGRAINE; NEUROMODULATION; NONHUMAN; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SLEEP DISORDER; STRUCTURE ACTIVITY RELATION; SYNAPTOGENESIS;

5'-NUCLEOTIDASE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; NUCLEOSIDES;

EID: 84887891549     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320340003     Document Type: Article

References (374)

1. Burnstock, G.; Fredholm, B.B.; Verkhratsky, A. Adenosine and ATP receptors in the brain. Curr. Top. Med. Chem., 2011, 11(8), 973-1011.
2. Burnstock, G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev., 2007, 87(2), 659-797.
3. Dobolyi, A.; Juhasz, G.; Kovacs, Z.; Kardos, J. Uridine function in the central nervous system. Curr. Top. Med. Chem., 2011, 11(8), 1058-1067.
4. Fields, R.D.; Burnstock, G. Purinergic signalling in neuron-glia interactions. Nat. Rev. Neurosci., 2006, 7(6), 423-436.
5. Haskó, Gy.; Sitkovsky, M.V.; Szabó, Cs. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol. Sci., 2004, 25(3), 152-157.
6. Schmidt, A.P.; Lara, D.R.; Souza, D.O. Proposal of a guaninebased purinergic system in the mammalian central nervous system. Pharmacol. Therapeut., 2007, 116(3), 401-416.
7. Burnstock, G.; Krügel, U.; Abbracchio, M.P.; Illes, P. Purinergic signalling: from normal behaviour to pathological brain function. Prog. Neurobiol., 2011, 95(2), 229-274.
8. Huang, Z.L.; Urade, Y.; Hayaishi, O. The role of adenosine in the regulation of sleep. Curr. Top. Med. Chem., 2011, 11(8), 1047-1057.
9. Lopes, L.V.; Sebastiao, A.M.; Ribeiro, J.A. Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr. Top. Med. Chem., 2011, 11(8), 1087-1101.
10. Sperlágh, B.; Vizi, E.S. The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects. Curr. Top. Med. Chem., 2011, 11(8), 1034-1046.
11. Kovacs, Z.; Dobolyi, A. Anatomical distribution of nucleoside system in the human brain and implications for therapy. In: Adenosine: a key link between metabolism and brain activity; Masino, S.A.; Boison, D., Eds.; Springer Science, Business Media: New York, 2013; pp. 621-656.
12. Ribeiro, J.A.; Sebastiao, A.M.; de Mendonca, A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol., 2002, 68(6), 377-392.
13. Jacobson, K.A.; Gao, Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug. Discov., 2006, 5(3), 247-264.
14. Boison, D. Modulators of nucleoside metabolism in the therapy of brain diseases. Curr. Top. Med. Chem., 2011, 11(8), 1068-1086.
15. Parkinson, F.E.; Damaraju, V.L.; Graham, K.; Yao, S.Y.M.; Baldwin, S.A.; Cass, C.E.; Young, J.D. Molecular biology of nucleoside transporters and their distributions and functions in the brain. Curr. Top. Med. Chem., 2011, 11(8), 948-972.
16. Kékesi, K.A.; Kovacs, Z.; Szilágyi, N.; Bobest, M.; Szikra, T.; Dobolyi, Á.; Juhász, G.; Palkovits, M. Concentration of nucleosides and related compounds in cerebral and cerebellar cortical areas and white matter of the human brain. Cell. Mol. Neurobiol., 2006, 26(4-6), 831-842.
17. Kovacs, Z.; Dobolyi, A. Functions and metabolism of brain nucleosides and their metabolites. Curr. Top. Med. Chem., 2011, 11(8), 907-908.
18. Kovacs, Z.; Dobolyi, Á.; Szikra, T.; Palkovits, M.; Juhász, G. Uneven regional distribution of nucleotide metabolism in human brain. Neurobiology (Bp), 1998, 6(3), 315-321.
19. Kovacs, Z.; Kékesi, K.A.; Bobest, M.; Török, T.; Szilágyi, N.; Szikra, T.; Szepesi, Zs.; Nyilas, R.; Dobolyi, Á.; Palkovits, M.; Juhász, G. Post mortem degradation of nucleosides in the brain: comparison of human and rat brains for estimation of in vivo concentration of nucleosides. J. Neurosci. Methods, 2005, 148(1), 88-93.
20. Kovacs, Z.; Dobolyi, A.; Juhász, G.; Kékesi, A.K. Nucleoside map of the human central nervous system. Neurochem. Res., 2010, 35(3), 452-464.
21. Kovacs, Z.; Juhász, G.; Dobolyi, A.; Bobest, M.; Papp, V.; Takáts, L.; Kékesi, K.A. Gender-and age-dependent changes in nucleoside levels in the cerebral cortex and white matter of the human brain. Brain Res. Bull., 2010, 81(6), 579-584.
22. Kovacs, Z.; Juhász, G.; Palkovits, M.; Dobolyi, A.; Kékesi, K.A. Area, age and gender dependence of the nucleoside system in the brain: a review of current literature. Curr. Top. Med. Chem., 2011, 11(8), 1012-1033.
23. Jennings, L.L.; Hao, C.; Cabrita, M.A.; Vickers, M.F.; Baldwin, S.A.; Young, J.; Cass, C.E. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology, 2001, 40(5), 722-731.
24. Fastbom, J.; Pazos, A.; Palacios, J.M. The distribution of adenosine A1 receptors and 5'-nucleotidase is the brain of some commonly used experimental animals. Neuroscience, 1987, 22(3), 813-826.
25. Fastbom, J.; Pazos, A.; Probst, A.; Palacios, J.M. Adenosine A1 receptors in the human brain: a quantitative autoradiographic study. Neuroscience, 1987, 22(3), 827-839.
26. Guillén-Gómez, E.; Calbet, M.; Casado, J.; de Lecea, L.; Soriano, E.; Pastor-Anglada, M.; Burgaya, F. Distribution of CNT2 and ENT1 transcripts in rat brain: selective decrease of CNT2 mRNA in the cerebral cortex of sleep-deprived rats. J. Neurochem., 2004, 90(4), 883-893.
27. Shan, D.; Haroutunian, V.; Meador-Woodruff, J.H.; McCullumsmith, R.E. Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia. Neuroreport, 2012, 23(4), 224-227.
28. Bonan, C.D. Ectonucleotidases and nucleotide/nucleoside transporters as pharmacological targets for neurological disorders. CNS Neurol. Disord. Drug Targets, 2012, 11(6), 739-750.
29. D'Alimonte, I.; D'Auro, M.; Citraro, R.; Biagioni, F.; Jiang, S.; Nargi, E.; Buccella, S.; Di Iorio, P.; Giuliani, P.; Ballerini, P.; Caciagli, F.; Russo, E.; De Sarro, G.; Ciccarelli, R. Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. Eur. J. Neurosci., 2009, 30(6), 1023-1035.
30. Dobolyi, A.; Szikra, T.; Kekesi, A.K.; Kovacs, Z.; Juhasz, G. Uridine is released by depolarization and inhibits unit activity in the rat hippocampus. Neuroreport, 1999, 10(14), 3049-3053.
31. Schrader, J.; Wahl, M.; Kuschinsky, W.; Kreutzberg, G.W. Increase of adenosine content in cerebral cortex of the cat during bicuculline-induced seizure. Pflugers Arch., 1980, 387(3), 245-251.
32. During, M.J.; Spencer, D.D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol., 1992, 32(5), 618-624.
33. Adén, U.; O'Connor, W.T.; Berman, R.F. Changes in purine levels and adenosine receptors in kindled seizures in the rat. Neuroreport, 2004, 15(10), 1585-1589.
34. Slézia, A.; Kékesi, A.K.; Szikra, T.; Papp, A.M.; Nagy, K.; Szente, M.; Maglóczky, Zs.; Freund, T.F.; Juhász, G. Uridine release during aminopyridine-induced epilepsy. Neurobiol. Dis., 2004, 16(3), 490-499.
35. Camici, M.; Micheli, V.; Ipata, P.L.; Tozzi, M.G. Pediatric neurological syndromes and inborn errors of purine metabolism. Neurochem. Int., 2010, 56(3), 367-378.
36. Löffler, M.; Fairbanks, L.D.; Zameitat, E.; Marinaki, A.M.; Simmonds, H.A. Pyrimidine pathways in health and disease. Trends Mol. Med., 2005, 11(9), 430-437.
37. Nyhan, W.L. Disorders of purine and pyrimidine metabolism. Mol. Genet. Metab., 2005, 86(1-2), 25-33.
38. Micheli, V.; Camici, M.; Tozzi, M.G.; Ipata, P.L.; Sestini, S.; Bertelli, M.; Pompucci, G. Neurological disorders of purine and pyrimidine metabolism. Curr. Top. Med. Chem., 2011, 11(8), 923-947.
39. Boison, D. Adenosine dysfunction in epilepsy. Glia, 2012, 60(8), 1234-1243.
40. Boison, D. Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies. Epilepsy Res., 2009, 85(2-3), 131-141.
41. Huber, A.; Padrun, V.; Déglon, N.; Aebischer, P.; Möhler, H.; Boison, D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc. Natl. Acad. Sci. U.S.A., 2001, 98(13), 7611-7616.
42. Boison, D.; Scheurer, L.; Tseng, J.L.; Aebischer, P.; Mohler, H. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp. Neurol., 1999, 160(1), 164-174.
43. Bortolotto, Z.A.; Mello, L.E.; Turski, L.; Cavalheiro, E.A. Effects of 2-chloroadenosine on amygdaloid and hippocampal kindled seizures. Arch. Int. Pharmacodyn. Ther., 1985, 277(2), 313-320.
44. Abdul-Ghani, A.S.; Attwell, P.J.; Bradford, H.F. The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdala-kindled seizures. Eur. J. Pharmacol., 1997, 326(1), 7-14.
45. Anschel, D.J.; Ortega, E.L.; Kraus, A.C.; Fisher, R.S. Focally injected adenosine prevents seizures in the rat. Exp. Neurol., 2004, 190(2), 544-547.
46. Dunwiddie, T.V.; Worth, T. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J. Pharmacol. Exp. Ther., 1982, 220(1), 70-76.
47. Rosen, J.B.; Berman, R.F. Differential effects of adenosine analogs on amygdala, hippocampus, and caudate nucleus kindled seizures. Epilepsia, 1987, 28(6), 658-666.
48. Yildirim, M.; Marangoz, C. Anticonvulsant effects of focal and intracerebroventricular adenosine on penicillin-induced epileptiform activity in rats. Brain Res., 2007, 1127(1), 193-200.
49. Masino, S.A.; Geiger, J.D. Are purines mediators of the anticonvulsant/ neuroprotective effects of ketogenic diets? Trends Neurosci., 2008, 31(6), 273-278.
50. Boison, D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist, 2005, 11(1), 25-36.
51. Boison, D. The adenosine kinase hypothesis of epileptogenesis. Prog. Neurobiol., 2008, 84(3), 249-262.
52. Pak, M.A.; Haas, H.L.; Decking, U.K.; Schrader, J. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacology, 1994, 33(9), 1049-1053.
53. Volonté, C.; D'Ambrosi, N. Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J., 2009, 276(1), 318-329.
54. Noji, T.; Karasawa, A.; Kusaka, H. Adenosine uptake inhibitors. Eur. J. Pharmacol., 2004, 495(1), 1-16.
55. Huang, N.K.; Lin, J.H.; Lin, J.T.; Lin, C.I.; Liu, E.M.; Lin, C.J.; Chen, W.P.; Shen, Y.C.; Chen, H.M.; Chen, J.B.; Lai, H.L.; Yang, C.W.; Chiang, M.C.; Wu, Y.S.; Chang, C.; Chen, J.F.; Fang, J.M.; Lin, Y.L.; Chern, Y. A new drug design targeting the adenosinergic system for Huntington's disease. PLoS One, 2011, 6(6), e20934.
56. Ipata, P.L. Origin, utilization, and recycling of nucleosides in the central nervous system. Adv. Physiol. Educ., 2011, 35(4), 342-346.
57. Ipata, P.L.; Camici, M.; Micheli, V.; Tozzi, M.G. Metabolic network of nucleosides in the brain. Curr. Top. Med. Chem., 2011, 11(8), 909-922.
58. Ipata, P.L.; Balestri, F.; Tozzi, M.G.; Camici, M. Brain nucleoside recycling. Metabolomics, 2012, DOI 10.1007/s11306-012-0457-x
59. Barsotti, C.; Ipata, P.L. Metabolic regulation of ATP breakdown and of adenosine production in rat brain extracts. Int. J. Biochem. Cell Biol., 2004, 36(11), 2214-2225.
60. Bavaresco, L.; Bernardi, A.; Braganhol, E.; Cappellari, A.R.; Rockenbach, L.; Farias, P.F.; Wink, M.R.; Delgado-Cañedo, A.; Battastini, A.M. The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation. Mol. Cell Biochem., 2008, 319(1-2), 61-68.
61. Schoen, S.W.; Kreutzberg, G.W. Synaptic 5'-nucleotidase activity reflects lesion-induced sprouting within the adult rat dentate gyrus. Exp. Neurol., 1994, 127(1), 106-118.
62. Cappellari, A.R.; Vasques, G.J.; Bavaresco, L.; Braganhol, E.; Battastini, A.M. Involvement of ecto-5'-nucleotidase/CD73 in U138MG glioma cell adhesion. Mol. Cell Biochem., 2012, 359(1-2), 315-322.
63. Braun, N.; Lenz, C.; Gillardon, F.; Zimmermann, M.; Zimmermann, H. Focal cerebral ischemia enhances glial expression of ecto-5'-nucleotidase. Brain Res., 1997, 766(1-2), 213-226.
64. Schoen, S.W.; Graeber, M.B.; Tóth, L.; Kreutzberg, G.W. 5'-Nucleotidase in postnatal ontogeny of rat cerebellum: a marker for migrating nerve cells? Brain Res., 1988, 467(1), 125-136.
65. Schoen, S.W.; Kreutzberg, G.W.; Singer, W. Cytochemical redistribution of 5'-nucleotidase in the developing cat visual cortex. Eur. J. Neurosci., 1993, 5(3), 210-222.
66. Schoen, S.W.; Kreutzberg, G.W. Evidence that 5'-nucleotidase is associated with malleable synapses an enzyme cytochemical investigation of the olfactory bulb of adult rats. Neuroscience, 1995, 65(1), 37-50.
67. Stanojevi, I.; Bjelobaba, I.; Nedeljkovi, N.; Drakuli, D.; Petrovi, S.; Stojiljkovi, M.; Horvat, A. Ontogenetic profile of ecto-5'-nucleotidase in rat brain synaptic plasma membranes. Int. J. Dev. Neurosci., 2011, 29(4), 397-403.
68. Lie, A.A.; Blümcke, I.; Beck, H.; Wiestler, O.D.; Elger, C.E.; Schoen, S.W. 5'-Nucleotidase activity indicates sites of synaptic plasticity and reactive synaptogenesis in the human brain. J. Neuropathol. Exp. Neurol., 1999, 58(5), 451-458.
69. Maienschein, V.; Zimmermann, H. Immunocytochemical localization of ecto-5'-nucleotidase in cultures of cerebellar granule cells. Neuroscience, 1996, 70(2), 429-438.
70. Heilbronn, A.; Maienschein, V.; Carstensen, K.; Gann, W.; Zimmermann, H. Crucial role of ecto-5'-nucleotidase in differentiation and survival of developing neural cells. Neuroreport, 1995, 7(1), 257-261.
71. Oses, J.P.; Batassini, C.; Pochmann, D.; Böhmer, A.E.; Vuaden, F.C.; Silvestrin, R.B.; Oliveira, A.; Bonan, C.D.; Bogo, M.R.; Souza, D.O.; Portela, L.V.; Sarkis, J.J.; Mello e Souza, T. The hydrolysis of striatal adenine-and guanine-based purines in a 6-hydroxydopamine rat model of Parkinson's disease. Neurochem. Res., 2011, 36(2), 215-222.
72. Grosso, S.; Rocchi, R.; Margollicci, M.; Vatti, G.; Luddi, A.; Marchi, F.; Balestri, P. Postictal serum nucleotidases activities in patients with epilepsy. Epilepsy Res., 2009, 84(1), 15-20.
73. Brunstein, M.G.; Silveira, E.M. Jr.; Chaves, L.S.; Machado, H.; Schenkel, O.; Belmonte-de-Abreu, P.; Souza, D.O.; Lara, D.R. Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatment. Neurosci. Lett., 2007, 414(1), 61-64.
74. Bruno, A.N.; Oses, J.P.; Bonan, C.D.; Walz, R.; Battastini, A.M.; Sarkis, J.J. Increase of nucleotidase activities in rat blood serum after a single convulsive injection of pentylenetetrazol. Neurosci. Res., 2002, 43(3), 283-288.
75. Bruno, A.N.; Oses, J.P.; Amaral, O.; Coitinho, A.; Bonan, C.D.; Battastini, A.M.; Sarkis, J.J. Changes in nucleotide hydrolysis in rat blood serum induced by pentylenetetrazol-kindling. Brain Res. Mol. Brain Res., 2003, 114(2), 140-145.
76. Bonan, C.D.; Walz, R.; Pereira, G.S.; Worm, P.V.; Battastini, A.M.; Cavalheiro, E.A.; Izquierdo, I.; Sarkis, J.J. Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy. Epilepsy Res., 2000, 39(3), 229-238.
77. Vianna, E.P.; Ferreira, A.T.; Doná, F.; Cavalheiro, E.A.; da Silva Fernandes, M.J. Modulation of seizures and synaptic plasticity by adenosinergic receptors in an experimental model of temporal lobe epilepsy induced by pilocarpine in rats. Epilepsia, 2005, 46(Suppl. 5), 166-173.
78. Oses, J.P.; Viola, G.G.; de Paula Cognato, G.; Júnior, V.H.; Hansel, G.; Böhmer, A.E.; Leke, R.; Bruno, A.N.; Bonan, C.D.; Bogo, M.R.; Portela, L.V.; Souza, D.O.; Sarkis, J.J. Pentylenetetrazol kindling alters adenine and guanine nucleotide catabolism in rat hippocampal slices and cerebrospinal fluid. Epilepsy Res., 2007, 75(2-3), 104-111.
79. Wardas, J. Neuroprotective role of adenosine in the CNS. Pol. J. Pharmacol., 2002, 54(4), 313-326.
80. Biber, K.; Pinto-Duarte, A.; Wittendorp, M.C.; Dolga, A.M.; Fernandes, C.C.; Von Frijtag Drabbe Künzel, J.; Keijser, J.N.; de Vries, R.; Ijzerman, A.P.; Ribeiro, J.A.; Eisel, U.; Sebastião, A.M.; Boddeke, H.W. Interleukin-6 upregulates neuronal adenosine A1 receptors: implications for neuromodulation and neuroprotection. Neuropsychopharmacology, 2008, 33(9), 2237-2250.
81. Hunsucker, S.A.; Mitchell, B.S.; Spychala, J. The 5'-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther., 2005, 107(1), 1-30.
82. Zimmermann, H. 5'-Nucleotidase: Molecular structure and functional aspects. Biochem. J., 1992, 285(Pt 2), 345-365.
83. Zimmermann, H. Ectonucleotidases in the nervous system. Novartis Found. Symp., 2006, 276, 113-128.
84. Latini, S.; Pedata, F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem., 2001, 79(3), 463-484.
85. Meghji, P. Storage, release, uptake, and inactivation of purines. Drug Develop. Res., 1993, 28(3), 214-219.
86. Zimmermann, H.; Braun, N.; Kegel, B.; Heine, P. New insights into molecular structure and function of ectonucleotidases in the nervous system. Neurochem. Int., 1998, 32(5-6), 421-425.
87. Grazia, T.M. Inborn errors in purine metabolism: role of 5'-nucleotidases and their involvement in the etiology of neurological impairments. Nucleosides Nucleotides Nucleic Acids, 2011, 30(12), 1276-1283.
88. Ipata, P.L.; Barsotti, C.; Tozzi, M.G.; Camici, M.; Balestri, F. Metabolic interplay between intra-and extra-cellular uridine metabolism via an ATP driven uridine-UTP cycle in brain. Int. J. Biochem. Cell Biol., 2010, 42(6), 932-937.
89. Brosh, S.; Sperling, O.; Dantziger, E.; Sidi, Y. Metabolism of guanine and guanine nucleotides in primary rat neuronal cultures. J. Neurochem., 1992, 58(4), 1485-1490.
90. Brosh, S.; Zoref-Shani, E.; Danziger, E.; Bromberg, Y.; Sperling, O.; Sidi, Y. Adenine nucleotide metabolism in primary rat neuronal cultures. Int. J. Biochem. Cell Biol., 1996, 28(3), 319-328.
91. Bianchi, V.; Spychala, J. Mammalian 5'-nucleotidases. J. Biol. Chem., 2003, 278(47), 46195-46198.
92. Rampazzo, C.; Mazzon, C.; Reichard, P.; Bianchi, V. 5'-Nucleotidases: specific assays for five different enzymes in cell extracts. Biochem. Biophys. Res. Commun., 2002, 293(1), 258-263.
93. Mackiewicz, M.; Geiger, J.D.; Pack, A.I. Simultaneous assessment of ecto-and cytosolic-5'-nucleotidase activities in brain micropunches. J. Neurosci. Methods, 2000, 104(1), 9-18.
94. Bontemps, F.; Vincent, M.F.; Van den Bergh, F.; van Waeg, G.; Van den Berghe, G. Stimulation by glycerate 2,3-bisphosphate: a common property of cytosolic IMP-GMP 5'-nucleotidase in rat and human tissues. Biochim. Biophys. Acta, 1989, 997(1-2), 131-134.
95. Moriwaki, Y.; Yamamoto, T.; Higashino, K. Enzymes involved in purine metabolism-a review of histochemical localization and functional implications. Histol. Histopathol., 1999, 14(4), 1321-1340.
96. Hunsucker, S.A.; Spychala, J.; Mitchell, B.S. Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance. J. Biol. Chem., 2001, 276(13), 10498-10504.
97. Sala-Newby, G.B.; Newby, A.C. Cloning of a mouse cytosolic 5'-nucleotidase-I identifies a new gene related to human autoimmune infertility-related protein. Biochim. Biophys. Acta, 2001, 1521(1-3), 12-18.
98. Marinaki, A.M.; Escuredo, E.; Duley, J.A.; Simmonds, H.A.; Amici, A.; Naponelli, V.; Magni, G.; Seip, M.; Ben-Bassat, I.; Harley, E.H.; Thein, S.L.; Rees, D.C. Genetic basis of hemolytic anemia caused by pyrimidine 5' nucleotidase deficiency. Blood, 2001, 97(11), 3327-3332.
99. Rampazzo, C.; Gallinaro, L.; Milanesi, E.; Frigimelica, E.; Reichard, P.; Bianchi, V. A deoxyribonucleotidase in mitochondria: involvement in regulation of dNTP pools and possible link to genetic disease. Proc. Natl. Acad. Sci. U.S.A., 2000, 97(15), 8239-8244.
100. Boyle, J.M.; Hey, Y.; Grzeschik, K.H.; Thompson, L.; Munro, E.; Fox, M. Regional localization of human ecto-5' nucleotidase to chromosome 6q14-q21. Hum. Genet., 1989, 83(2), 179-180.
101. Zimmermann, H. Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog. Neurobiol., 1996, 49(6), 589-618.
102. Vogel, M.; Kowalewski, H.; Zimmermann, H.; Hooper, N.M.; Turner, A.J. Soluble low-Km 5'-nucleotidase from electric-ray (Torpedo marmorata) electric organ and bovine cerebral cortex is derived from the glycosyl- phosphatidylinositol-anchored ectoenzyme by phospholipase C cleavage. Biochem. J., 1992, 284(Pt 3), 621-624.
103. Meflah, K.; Harb, J.; Duflos, Y.; Bernard, S. 5'-Nucleotidase from bovine caudate nucleus synaptic plasma membranes: specificity for substrates and cations; study of the carbohydrate moiety by glycosidases. J. Neurochem., 1984, 42(4), 1107-1115.
104. Burger, R.M.; Lowenstein, J.M. 5'-Nucleotidase from smooth muscle of small intestine and from brain. Inhibition of nucleotides. Biochemistry, 1975, 14(11), 2362-2366.
105. Camici, M.; Fini, C.; Ipata, P.L. Isolation and kinetic properties of 5'-nucleotidase from guinea-pig skeletal muscle. Biochim. Biophys. Acta, 1985, 840(1), 6-12.
106. Zimmermann, H. Extracellular purine metabolism. Drug. Develop. Res., 1996, 39(3-4), 337-352.
107. Naito, Y.; Lowenstein, J.M. 5'-Nucleotidase from rat heart membranes. Inhibition by adenine nucleotides and related compounds. Biochem. J., 1985, 226(3), 645-651.
108. Bonan, C.D.; Dias, M.M.; Battastini, A.M.; Dias, R.D.; Sarkis, J.J. Inhibitory avoidance learning inhibits ectonucleotidases activities in hippocampal synaptosomes of adult rats. Neurochem. Res., 1998, 23(7), 977-982.
109. Sowa, N.A.; Taylor-Blake, B.; Zylka, M.J. Ecto-5'-nucleotidase (CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive circuits. J. Neurosci., 2010, 30(6), 2235-2244.
110. Kawashima, Y.; Nagasawa, T.; Ninomiya, H. Contribution of ecto-5'-nucleotidase to the inhibition of platelet aggregation by human endothelial cells. Blood, 2000, 96(6), 2157-2162.
111. Thomson, S.; Bao, D.; Deng, A.; Vallon, V. Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. J. Clin. Invest., 2000, 106(2), 289-298.
112. Kitakaze, M.; Minamino, T.; Node, K.; Komamura, K.; Shinozaki, Y.; Chujo, M.; Mori, H.; Inoue, M.; Hori, M.; Kamada, T. Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of K+c channels. Am. J. Physiol., 1996, 270(5 Pt 2), 1744-1756.
113. Pedrazza, E.L.; Riboldi, G.P.; Pereira, G.S.; Izquierdo, I.; Bonan, C.D. Habituation to an open field alters ecto-nucleotidase activities in rat hippocampal synaptosomes. Neurosci. Lett., 2007, 413(1), 21-24.
114. Zlomuzica, A.; Burghoff, S.; Schrader, J.; Dere, E. Superior working memory and behavioural habituation but diminished psychomotor coordination in mice lacking the ecto-5'-nucleotidase (CD73) gene. Purinergic Signal., 2012, Dec 29. [Epub ahead of print]; DOI: 10.1007/s11302-012-9344-1
115. Cunha, R.A. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signal., 2005, 1(2), 111-134.
116. Alanko, L.; Heiskanen, S.; Stenberg, D.; Porkka-Heiskanen, T. Adenosine kinase and 5'-nucleotidase activity after prolonged wakefulness in the cortex and the basal forebrain of rat. Neurochem. Int., 2003, 42(6), 449-454.
117. Burnstock, G. The purinergic nerve hypothesis. Ciba Found. Symp., 1977, 48, 295-314.
118. Cunha, R.A. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem. Int., 2001, 38(2), 107-125.
119. Massaia, M.; Perrin, L.; Bianchi, A.; Ruedi, J.; Attisano, C.; Altieri, D.; Rijkers, G.T.; Thompson, L.F. Human T cell activation. Synergy between CD73 (ecto-5'-nucleotidase) and signals delivered through CD3 and CD2 molecules. J. Immunol., 1990, 145(6), 1664-1674.
120. Resta, R.; Yamashita, Y.; Thompson, L.F. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev., 1998, 161, 95-109.
121. Zimmermann, H.; Zebisch, M.; Sträter, N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal., 2012, 8(3), 437-502.
122. Zhi, X.; Chen, S.; Zhou, P.; Shao, Z.; Wang, L.; Ou, Z.; Yin, L. RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin. Exp. Metastasis, 2007, 24(6), 439-448.
123. Wurm, A.; Lipp, S.; Pannicke, T.; Linnertz, R.; Krügel, U.; Schulz, A.; Färber, K.; Zahn, D.; Grosse, J.; Wiedemann, P.; Chen, J.; Schöneberg, T.; Illes, P.; Reichenbach, A.; Bringmann, A. Endogenous purinergic signaling is required for osmotic volume regulation of retinal glial cells. J. Neurochem., 2010, 112(5), 1261-1272.
124. Colgan, S.P.; Eltzschig, H.K.; Eckle, T.; Thompson, L.F. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal., 2006, 2(2), 351-360.
125. Koszalka, P.; Ozüyaman, B.; Huo, Y.; Zernecke, A.; Flögel, U.; Braun, N.; Buchheiser, A.; Decking, U.K.; Smith, M.L.; Sévigny, J.; Gear, A.; Weber, A.A.; Molojavyi, A.; Ding, Z.; Weber, C.; Ley, K.; Zimmermann, H.; Gödecke, A.; Schrader, J. Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res., 2004, 95(8), 814-821.
126. Petrovic-Djergovic, D.; Hyman, M.C.; Ray, J.J.; Bouis, D.; Visovatti, S.H.; Hayasaki, T.; Pinsky, D.J. Tissue-resident ecto-5' nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain. J. Immunol., 2012, 188(5), 2387-2398.
127. Koos, B.J.; Kruger, L.; Murray, T.F. Source of extracellular brain adenosine during hypoxia in fetal sheep. Brain Res., 1997, 778(2), 439-442.
128. Skladanowski, A.C.; Newby, A.C. Partial purification and properties of an AMP-specific soluble 5'-nucleotidase from pigeon heart. Biochem. J., 1990, 268(1), 117-122.
129. Darvish, A.; Metting, P.J. Purification and regulation of an AMPspecific cytosolic 5'-nucleotidase from dog heart. Am. J. Physiol., 1993, 264(5 Pt 2), 1528-1534.
130. Skladanowski, A.C.; Newby, A.C.; Makarewicz, W. Purification and some molecular properties of pigeon heart AMP-selective 5'-nucleotidase. Adv. Exp. Med. Biol., 1998, 431, 113-117.
131. Garvey, E.P.; Lowen, G.T.; Almond, M.R. Nucleotide and nucleoside analogues as inhibitors of cytosolic 5'-nucleotidase I from heart. Biochemistry, 1998, 37(25), 9043-9051.
132. Cross, H.R.; Murphy, E.; Black, R.G.; Auchampach, J.; Steenbergen, C. Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am. J. Physiol. Heart Circ. Physiol., 2002, 283(4), 1562-1568.
133. Ipata, P.L.; Tozzi, M.G. Recent advances in structure and function of cytosolic IMP-GMP specific 5'-nucleotidase II (cN-II). Purinergic Signal., 2006, 2(4), 669-675.
134. Galmarini, C.M.; Jordheim, L.; Dumontet, C. Role of IMPselective 5'-nucleotidase (cN-II) in hematological malignancies. Leuk. Lymphoma, 2003, 44(7), 1105-1111.
135. Oka, J.; Matsumoto, A.; Hosokawa, Y.; Inoue, S. Molecular cloning of human cytosolic purine 5'-nucleotidase. Biochem. Biophys. Res. Commun., 1994, 205(1), 917-922.
136. Rampazzo, C.; Gazziola, C.; Ferraro, P.; Gallinaro, L.; Johansson, M.; Reichard, P.; Bianchi, V. Human high-Km 5'-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells. Eur. J. Biochem., 1999, 261(3), 689-697.
137. Pesi, R.; Allegrini, S.; Careddu, M.G.; Filoni, D.N.; Camici, M.; Tozzi, M.G. Active and regulatory sites of cytosolic 5'-nucleotidase. FEBS J., 2010, 277(23), 4863-4872.
138. Spychala, J.; Chen, V.; Oka, J.; Mitchell, B.S. ATP and phosphate reciprocally affect subunit association of human recombinant High Km 5'-nucleotidase. Role for the C-terminal polyglutamic acid tract in subunit association and catalytic activity. Eur. J. Biochem., 1999, 259(3), 851-858.
139. Spychaa, J.; Madrid-Marina, V.; Fox, I.H. High Km soluble 5'-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. J. Biol. Chem., 1988, 263(35), 18759-18765.
140. Pesi, R.; Turriani, M.; Allegrini, S.; Scolozzi, C.; Camici, M.; Ipata, P.L.; Tozzi, M.G. The bifunctional cytosolic 5'-nucleotidase: regulation of the phosphotransferase and nucleotidase activities. Arch. Biochem. Biophys., 1994, 312(1), 75-80.
141. Allegrini, S.; Pesi, R.; Tozzi, M.G.; Fiol, C.J.; Johnson, R.B.; Eriksson, S. Bovine cytosolic IMP/GMP-specific 5'-nucleotidase: cloning and expression of active enzyme in Escherichia coli. Biochem. J., 1997, 328(Pt 2), 483-487.
142. Tozzi, M.G.; Camici, M.; Pesi, R.; Allegrini, S.; Sgarrella, F.; Ipata, P.L. Nucleoside phosphotransferase activity of human colon carcinoma cytosolic 5'-nucleotidase. Arch. Biochem. Biophys., 1991, 291(2), 212-217.
143. Borowiec, A.; Lechward, K.; Tkacz-Stachowska, K.; Skadanowski, A.C. Adenosine as a metabolic regulator of tissue function: production of adenosine by cytoplasmic 5'-nucleotidases. Acta Biochim. Pol., 2006, 53(2), 269-278.
144. Careddu, M.G.; Allegrini, S.; Pesi, R.; Camici, M.; Garcia-Gil, M.; Tozzi, M.G. Knockdown of cytosolic 5'-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells. Biochim. Biophys. Acta., 2008, 1783(8), 1529-1535.
145. Swallow, D.M.; Turner, V.S.; Hopkinson, D.A. Isozymes of rodent 5'-nucleotidase: evidence for two independent structural loci Umph-1 and Umph-2. Ann. Hum. Genet., 1983, 47(Pt 1), 9-17.
146. Lu, M.M.; Chen, F.; Gitler, A.; Li, J.; Jin, F.; Ma, X.K.; Epstein, J.A. Cloning and expression analysis of murine lupin, a member of a novel gene family that is conserved through evolution and associated with Lupus inclusions. Dev. Genes Evol., 2000, 210(10), 512-517.
147. Amici, A.; Magni, G. Human erythrocyte pyrimidine 5'-nucleotidase, PN-I. Arch. Biochem. Biophys., 2002, 397(2), 184-190.
148. Rees, D.C.; Duley, J.A.; Marinaki, A.M. Pyrimidine 5' nucleotidase deficiency. Br. J. Haematol., 2003, 120(3), 375-383.
149. Rampazzo, C.; Johansson, M.; Gallinaro, L.; Ferraro, P.; Hellman, U.; Karlsson, A.; Reichard, P.; Bianchi, V. Mammalian 5'(3')-deoxyribonucleotidase, cDNA cloning, and overexpression of the enzyme in Escherichia coli and mammalian cells. J. Biol. Chem., 2000, 275(8), 5409-5415.
150. Höglund, L.; Reichard, P. Cytoplasmic 5'(3')-nucleotidase from human placenta. J. Biol. Chem., 1990, 265(12), 6589-6595.
151. Rampazzo, C.; Kost-Alimova, M.; Ruzzenente, B.; Dumanski, J.P.; Bianchi, V. Mouse cytosolic and mitochondrial deoxyribonucleotidases: cDNA cloning of the mitochondrial enzyme, gene structures, chromosomal mapping and comparison with the human orthologs. Gene, 2002, 294(1-2), 109-117.
152. Amici, A.; Emanuelli, M.; Magni, G.; Raffaelli, N.; Ruggieri, S. Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides. FEBS Lett., 1997, 419(2-3), 263-267.
153. Mazzon, C.; Rampazzo, C.; Scaini, M.C.; Gallinaro, L.; Karlsson, A.; Meier, C.; Balzarini, J.; Reichard, P.; Bianchi, V. Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. Biochem. Pharmacol., 2003, 66(3), 471-479.
154. Gazziola, C.; Ferraro, P.; Moras, M.; Reichard, P.; Bianchi, V. Cytosolic high K(m) 5'-nucleotidase and 5'(3')-deoxyribonucleotidase in substrate cycles involved in nucleotide metabolism. J. Biol. Chem., 2001, 276(9), 6185-6190.
155. Fritzson, P. Regulation of nucleotidase activities in animal tissues. Adv. Enzyme Regul., 1977, 16, 43-61.
156. Gallinaro, L.; Crovatto, K.; Rampazzo, C.; Pontarin, G.; Ferraro, P.; Milanesi, E.; Reichard, P.; Bianchi, V. Human mitochondrial 5'- deoxyribonucleotidase. Overproduction in cultured cells and functional aspects. J. Biol. Chem., 2002, 277(38), 35080-35087.
157. Rinaldo-Matthis, A.; Rampazzo, C.; Reichard, P.; Bianchi, V.; Nordlund, P. Crystal structure of a human mitochondrial deoxyribonucleotidase. Nat. Struct. Biol., 2002, 9(10), 779-787.
158. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 2009, 33(4), 307-320.
159. Van Rompay, A.R.; Johansson, M.; Karlsson, A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol. Ther., 2003, 100(2), 119-139.
160. Pastor-Anglada, M.; Cano-Soldado, P.; Molina-Arcas, M.; Lostao, M.P.; Larráyoz, I.; Martínez-Picado, J.; Casado, F.J. Cell entry and export of nucleoside analogues. Virus Res., 2005, 107(2), 151-164.
161. Johnson, M.A.; Fridland, A. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol. Pharmacol., 1989, 36(2), 291-295.
162. Gallier, F.; Lallemand, P.; Meurillon, M.; Jordheim, L.P.; Dumontet, C.; Périgaud, C.; Lionne, C.; Peyrottes, S.; Chaloin, L. Structural insights into the inhibition of cytosolic 5'-nucleotidase II (cNII) by ribonucleoside 5'-monophosphate analogues. PLoS Comput. Biol., 2011, 7(12), e1002295.
163. Itoh, R.; Oka, J. Evidence for existence of a cytosol 5'-nucleotidase in chicken heart: comparison of some properties of heart and liver enzymes. Comp.
164. Skladanowski, A.C.; Hoffmann, C.; Krass, J.; Jastorff, B.; Makarewicz, W. Structure-activity relationship of cytoplasmic 5'-nucleotidase substrate sites. Biochem. J., 1996, 314(Pt 3), 1001-1007.
165. Orozco, M.; Canela, E.I.; Franco, R. A quantum chemical study of the enzymatic deamination of benzoadenine derivatives. A theoretical model of the interactions occurring between nucleosides and the active site of adenosine deaminase. Eur. J. Biochem., 1990, 188(1), 155-163.
166. Walldén, K.; Stenmark, P.; Nyman, T.; Flodin, S.; Gräslund, S.; Loppnau, P.; Bianchi, V.; Nordlund, P. Crystal structure of human cytosolic 5'-nucleotidase II: insights into allosteric regulation and substrate recognition. J. Biol. Chem., 2007, 282(24), 17828-17836.
167. Allegrini, S.; Scaloni, A.; Ferrara, L.; Pesi, R.; Pinna, P.; Sgarrella, F.; Camici, M.; Eriksson, S.; Tozzi, M.G. Bovine cytosolic 5'-nucleotidase acts through the formation of an aspartate 52-phosphoenzyme intermediate. J. Biol. Chem., 2001, 276(36), 33526-33532.
168. Lahiri, S.D.; Zhang, G.; Dunaway-Mariano, D.; Allen, K.N. The pentacovalent phosphorus intermediate of a phosphoryl transfer reaction. Science, 2003, 299(5615), 2067-2071.
169. Walldén, K.; Nordlund, P. Structural basis for the allosteric regulation and substrate recognition of human cytosolic 5'-nucleotidase II. J. Mol. Biol., 2011, 408(4), 684-696.
170. Grobosky, C.L.; Lopez, J.B.; Rennie, S.; Skopelitis, D.J.; Wiest, A.T.; Bingman, C.A.; Bitto, E. Structural basis of substrate specificity and selectivity of murine cytosolic 5'-nucleotidase III. J. Mol. Biol., 2012, 423(4), 540-554.
171. Knöfel, T.; Sträter, N. E. coli 5'-nucleotidase undergoes a hingebending domain rotation resembling a ball-and-socket motion. J. Mol. Biol., 2001, 309(1), 255-266.
172. Shi, N.; Zhang, Y.J.; Chen, H.K.; Gao, Y.; Teng, M.; Niu, L. Crystal structure of the pyrimidine 5'-nucleotidase SDT1 from Saccharomyces cerevisiae complexed with uridine 5'-monophosphate provides further insight into ligand binding. Proteins, 2011, 79(4), 1358-1362.
173. Schultz-Heienbrok, R.; Maier, T.; Sträter, N. A large hinge bending domain rotation is necessary for the catalytic function of Escherichia coli 5'-nucleotidase. Biochemistry, 2005, 44(7), 2244-2252.
174. Heuts, D.P.; Weissenborn, M.J.; Olkhov, R.V.; Shaw, A.M.; Gummadova, J.; Levy, C.; Scrutton, N.S. Crystal structure of a soluble form of human CD73 with ecto-5'-nucleotidase activity. Chembiochem., 2012, 13(16), 2384-2391.
175. Knapp, K.M.; Zebisch, M.; Sträter, N. Crystallization and preliminary X-ray analysis of the open form of human ecto-5'-nucleotidase (CD73). Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun., 2012, 68(Pt 12), 1545-1549.
176. Knapp, K.; Zebisch, M.; Pippel, J.; El-Tayeb, A.; Müller, C.E.; Sträter, N. Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure, 2012, 20(12), 2161-2173.
177. Bowley, M.P.; Drevets, W.C.; Öngür, D.; Price, J.L. Low glial numbers in the amygdala in major depressive disorder. Biol. Psychiatry, 2002, 52(5), 404-412.
178. Brauch, R.A.; Adnan El-Masri, M.; Parker, J.C. Jr.; El-Mallakh, R.S. Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. J. Affect. Disord., 2006, 91(1), 87-90.
179. Harper, D.G.; Stopa, E.G.; Kuo-Leblanc, V.; McKee, A.C.; Asayama, K.; Volicer, L.; Kowall, N.; Satlin, A. Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia. Brain, 2008, 131(Pt 6), 1609-1617.
180. Öngür, D.; Drevets, W.C.; Price, J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(22), 13290-13295.
181. Roos, R.A.; Bots, G.T.; Hermans, J. Neuronal nuclear membrane indentation and astrocyte/neuron ratio in Huntington's disease. A quantitative electron microscopic study. J. Hirnforsch., 1985, 26(6), 689-693.
182. Deckert, J.; Abel, F.; Kunig, G.; Hartmann, J.; Senitz, D.; Maier, H.; Ransmayr, G.; Riederer, P. Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity. Neurosci. Lett., 1998, 244(1), 1-4.
183. Jenner, P.; Mori, A.; Hauser, R.; Morelli, M.; Fredholm, B.B.; Chen, J.F. Adenosine, adenosine A2A antagonists, and Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15(6), 406-413.
184. Fuxe, K.; Marcellino, D.; Borroto-Escuela, D.O.; Guescini, M.; Fernández-Dueñas, V.; Tanganelli, S.; Rivera, A.; Ciruela, F.; Agnati, L.F. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther., 2010, 16(3), 18-42.
185. Morelli, M.; Carta, A.R.; Kachroo, A.; Schwarzschild, M.A. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog. Brain Res., 2010, 183, 183-208.
186. Dall'Igna, O.P.; Fett, P.; Gomes, M.W.; Souza, D.O.; Cunha, R.A.; Lara, D.R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol., 2007, 203(1), 241-245.
187. Linden, J.; Rosin, D.L. Purinergic systems. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects; Siegel, G.; Albers, R.W.; Brady, S.; Price, D., Eds.; Elsevier, Academic Press Inc.: New York, 2006; pp. 303-316.
188. Watts, R.W. Molecular variation in relation to purine metabolism. J. Clin. Pathol. Suppl. (R. Coll. Pathol.), 1974, 8, 48-63.
189. Balestri, F.; Barsotti, C.; Lutzemberger, L.; Camici, M.; Ipata, P.L. Key role of uridine kinase and uridine phosphorylase in the homeostatic regulation of purine and pyrimidine salvage in brain. Neurochem. Int., 2007, 51(8), 517-523.
190. Dunwiddie, T.V.; Masino, S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci., 2001, 24, 31-55.
191. Allsop, J.; Watts, R. W. E. Purine de novo synthesis in liver and developing rat brain, and the effect of some inhibitors of purine nucleotide interconversion. Enzyme, 1983, 30(3), 172-180.
192. Barsotti, C.; Tozzi, M.G.; Ipata, P.L. Purine and pyrimidine salvage in whole rat brain. Utilization of ATP-derived ribose-1-phosphate and 5-phosphoribosyl-1-pyrophosphate generated in experiments with dialyzed cell-free extracts. J. Biol. Chem., 2002, 277(12), 9865-9869.
193. Mascia, L.; Cotrufo, T.; Cappiello, M.; Ipata, P.L. Ribose 1-phosphate and inosine activate uracil salvage in rat brain. Biochim. Biophys. Acta, 1999, 1472(1-2), 93-98.
194. Mascia, L.; Turchi, G.; Bemi, V.; Ipata, P.L. Uracil salvage pathway in PC12 cells. Biochim. Biophys. Acta, 2001, 1524(1), 45-50.
195. Arch, J.R.; Newsholme, E.A. Activities and some properties of 5'-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates and invertebrates in relation to the control of the concentration and the physiological role of adenosine. Biochem. J., 1978, 174(3), 965-977.
196. Iriyama, K.; Iwamoto, T.; Yoshiura, M.; Aoki, T. Post-mortem changes in uric acid and ascorbic acid in human cerebral cortex tissues excised after cardiac death. Biochem. Med. Metab. Biol., 1986, 36(2), 186-193.
197. Bjelobaba, I.; Stojiljkovic, M.; Pekovic, S.; Dacic, S.; Lavrnja, I.; Stojkov, D.; Rakic, L.; Nedeljkovic, N. Immunohistological determination of ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1) and 5'-nucleotidase in rat hippocampus reveals overlapping distribution. Cell. Mol. Neurobiol., 2007, 27(6), 731-743.
198. Fernández, J.R.; Sweet, E.S.; Welsh, W.J.; Firestein, B.L. Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine. Bioorg. Med. Chem., 2010, 18(18), 6748-6755.
199. Firestein, B.L.; Brenman, J.E.; Aoki, C.; Sanchez-Perez, A.M.; El-Husseini, A.E.; Bredt, D.S. Cypin: a cytosolic regulator of PSD-95 postsynaptic targeting. Neuron, 1999, 24(3), 659-672.
200. Yegutkin, G.G. Nucleotide-and nucleoside converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta, 2008, 1783(5), 673-694.
201. Gracia, E.; Cortés, A.; Meana, J.J.; García-Sevilla, J.; Herhsfield, M.S.; Canela, E.I.; Mallol, J.; Lluís, C.; Franco, R.; Casadó, V. Human adenosine deaminase as an allosteric modulator of human A(1) adenosine receptor: abolishment of negative cooperativity for [H](R)-pia binding to the caudate nucleus. J. Neurochem., 2008, 107(1), 161-170.
202. Todorov, L.D.; Mihaylova-Todorova, S.; Westfall, T.D.; Sneddon, P.; Kennedy, C.; Bjur, R.A.; Westfall, D.P. Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation. Nature, 1997, 387(6628), 76-79.
203. Dawson, D.M. Absence of guanine deaminase from cerebellum. Neurology, 1971, 21(6), 621-626.
204. Nagata, H.; Mimori, Y.; Nakamura, S.; Kameyama, M. Regional and subcellular distribution in mammalian brain of the enzymes producing adenosine. J. Neurochem., 1984, 42(4), 1001-1007.
205. Norstrand, I.F.; Siverls, V.C.; Libbin, R.M. Regional distribution of adenosine deaminase in the human neuraxis. Enzyme, 1984, 32(1), 20-25.
206. Norstrand, I.F.; Glantz, M.D. Topographical distribution of purine nucleoside phosphorylase in the human neuraxis. Enzyme, 1980, 25(2), 118-122.
207. Phillips, E.; Newsholme, E.A. Maximum activities, properties and distribution of 5'-nucleotidase, adenosine kinase and adenosine deaminase in rat and human brain. J. Neurochem., 1979, 33(2), 553-558.
208. Mackiewicz, M.; Nikonova, E.V.; Zimmermann, J.E.; Romer, M.A.; Cater, J.; Galante, R.J.; Pack, A.I. Age-related changes in adenosine metabolic enzymes in sleep/wake regulatory areas of the brain. Neurobiol. Aging, 2006, 27(2), 351-360.
209. Jin, Z.L.; Lee, T.F.; Zhou, S.J.; Wang, L.C. Age-dependent change in the inhibitory effect of an adenosine agonist on hippocampal acetylcholine release in rats. Brain Res. Bull., 1993, 30(1-2), 149-152.
210. Fuchs, J.L. 5'-nucleotidase activity increases in aging rat brain. Neurobiol. Aging, 1991, 12(5), 523-530.
211. Rucker, B.; Pereira, G.S.; Furstenau, C.R.; Izquierdo, I.; Bonan, C.D.; Sarkis, J.J. Inhibitory avoidance task reveals differences in ectonucleotidase activities between male and female rats. Neurochem. Res., 2004, 29(12), 2231-2237.
212. De Paula, C.G.; Bruno, A.N.; Vuaden, F.C.; Sarkis, J.J.; Bonan, C.D. Ontogenetic profile of ectonucleotidase activities from brain synaptosomes of pilocarpine-treated rats. Int. J. Dev. Neurosci., 2005, 23(8), 703-709.
213. Collado, P.; Guillamón, A.; Valencia, A.; Segovia, S. Sexual dimorphism in the bed nucleus of the accessory olfactory tract in the rat. Brain Res. Dev. Brain Res., 1990, 56(2), 263-268.
214. Podgorska, M.; Kocbuch, K.; Pawelczyk, T. Recent advences in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim. Pol., 2005, 52(4), 749-758.
215. Baldwin, S.A.; Yao, S.Y.M.; Hyde, R.J.; Ng, A.M.L.; Foppolo, S.; Barnes, K.; Ritzel, M.W.L.; Cass, C.E.; Young, J.D. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J. Biol. Chem., 2005, 280(16), 15880-15887.
216. Barnes, K.; Dobrzynski, H.; Foppolo, S.; Beal, P.R.; Ismat, F.; Scullion, E.R.; Sun, L.; Tellez, J.; Ritzel, M.W.; Claycomb, W.C.; Cass, C.E.; Young, J.D.; Billeter-Clark, R.; Boyett, M.R.; Baldwin, S.A. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ. Res., 2006, 99(5), 510-519.
217. Pennycooke, M.; Chaudary, N.; Shuralyova, I.; Zhang, Y.; Coe, I.R. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem. Biophys. Res. Commun., 2001, 280(3), 951-959.
218. Ritzel, M.W.L.; Ng, A.M.L.; Yao, S.Y.M.; Graham, K.; Loewen, S.K.; Smith, K.M.; Ritzel, R.G.; Mowles, D.A.; Carpenter, P.; Chen, X.Z.; Karpinski, E.; Hyde, R.J.; Baldwin, S.A.; Cass, C.E.; Young, J.D. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem., 2001, 276(4), 2914-2927.
219. Sebastião, A.M.; Ribeiro, J.A. Fine-tuning neuromodulation by adenosine. Trends Pharmacol. Sci., 2000, 21(9), 341-346.
220. Fredholm, B.B.; Ijzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53(4), 527-552.
221. Rittiner, J.E.; Korboukh, I.; Hull-Ryde, E.A.; Jin, J.; Janzen, W.P.; Frye, S.V.; Zylka, M.J. AMP is an adenosine A1 receptor agonist. J. Biol. Chem., 2012, 287(8), 5301-5309.
222. Shin, H.K.; Park, S.N.; Hong, K.W. Implication of adenosine A2A receptors in hypotension-induced vasodilation and cerebral blood flow autoregulation in rat pial arteries. Life Sci., 2000, 67(12), 1435-1445.
223. Cornfield, L.J.; Hu, S.; Hurt, S.D.; Sills, M.A. [3H]2- phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. J. Pharmacol. Exp. Ther., 1992, 263(2), 552-561.
224. Luthin, D.R.; Linden, J. Comparison of A4 and A2A binding sites in striatum and COS cells transfected with adenosine A2A receptors. J. Pharmacol. Exp. Ther., 1995, 272(2), 511-518.
225. Tucker, A.L.; Linden, J. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc. Res., 1993, 27(1), 62-67.
226. Bender, E.; Buist, A.; Jurzak, M.; Langlois, X.; Baggerman, G.; Verhasselt, P.; Ercken, M.; Guo, H.Q.; Wintmolders, C.; Van den Wyngaert, I.; Van Oers, I.; Schoofs, L.; Luyten, W. Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proc. Natl. Acad. Sci. U.S.A., 2002, 99(13), 8573-8578.
227. Borrmann, T.; Abdelrahman, A.; Volpini, R.; Lambertucci, C.; Alksnis, E.; Gorzalka, S.; Knospe, M.; Schiedel, A.C.; Cristalli, G.; Müller, C.E. Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. J. Med. Chem., 2009, 52(19), 5974-5989.
228. Kimura, T.; Ho, I.K.; Yamamoto, I. Uridine receptor: discovery and its involvement in sleep mechanism. Sleep, 2001, 24(3), 251-260.
229. Schulte, G.; Fredholm, B.B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal., 2003, 15(9), 813-827.
230. Traversa, U.; Bombi, G.; Di Iorio, P.; Ciccarelli, R.; Werstiuk, E.S.; Rathbone, M.P. Specific [(3)H]-guanosine binding sites in rat brain membranes. Br. J. Pharmacol., 2002, 135(4), 969-976.
231. Svenningsson, P.; Hall, H.; Sedvall, G.; Fredholm, B.B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse, 1997, 27(4), 322-335.
232. Fastbom, J.; Pazos, A.; Probst, A.; Palacios, J.M. Adenosine A1 receptors is human brain: characterisation and autoradiographic visualization. Neurosci. Lett., 1986, 65(2), 127-132.
233. Castillo, C.A.; Albasanz, J.L.; León, D.; Jordán, J.; Pallás, M.; Camins, A.; Martín, M. Age-related expression of adenosine receptors in brain from the senescense-accerelated mouse. Exp. Gerontol., 2009, 44(6-7), 453-461.
234. Xu, K.; Bastia, E.; Schwarzschild, M. Therapautic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol. Ther., 2005, 105(3), 267-310.
235. Sperlágh, B.; Zsilla, G.; Baranyi, M.; Kékes-Szabó, A.; Vizi, E.S. Age-dependent changes of presynaptic neuromodulation via A1-adenosine receptors in rat hippocampal slices. Int. J. Dev. Neurosci., 1997, 15(6), 739-747.
236. Johansson, B.; Georgiev, V.; Fredholm, B.B. Distribution and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors. Neuroscience, 1997, 80(4), 1187-1207.
237. Cunha, R.A.; Constantino, M.C.; Sebastião, A.M.; Ribeiro, J.A. Modification of A1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport, 1995, 6(11), 1583-1588.
238. Ekonomou, A.; Pagonopoulou, O.; Angelatou, F. Age-dependent changes in adenosine A1 receptor and uptake site binding in the mouse brain: an autoradiographic study. J. Neurosci. Res., 2000, 60(2), 257-265.
239. Meyer, P.T.; Elmenhorst, D.; Boy, C.; Winz, O.; Matusch, A.; Zilles, K.; Bauer, A. Effect of aging on cerebral A1 adenosine receptors: a [18F]CPFPX PET study in humans. Neurobiol. Aging, 2007, 28(12), 1914-1924.
240. Lopes, L.V.; Cunha, R.A.; Ribeiro, J.A. Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A2A receptors in the limbic cortex, but not striatum, of aged rats. J. Neurochem., 1999, 73(4), 1733-1738.
241. Muir, J.L. Acetylcholine, aging, and Alzheimer's disease. Pharmacol. Biochem. Behav., 1997, 56(4), 687-696.
242. Cunha, R.A.; Johansson, B.; Fredholm, B.B.; Ribeiro, J.A.; Sebastiao, A.M. Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci. Lett., 1995, 196(1-2), 41-44.
243. Geiger, J.D.; Nagy, J.I. Distribution of adenosine deaminase activity in rat brain and spinal cord. J. Neurosci., 1986, 6(9), 2707-2714.
244. Ceballos, G.; Tuttle, J.B.; Rubio, R. Differential distribution of purine metabolizing enzymes between glia and neurons. J. Neurochem., 1994, 62(3), 1144-1153.
245. Zoref-Shani, E.; Bromberg, Y.; Lilling, G.; Gozes, I.; Brosh, S.; Sidi, Y.; Sperling, O. Developmental changes in purine nucleotide metabolism in cultured rat astroglia. Int. J. Dev. Neurosci., 1995, 13(8), 887-896.
246. Thörner, G.; Lange, H.; Hopf, A. Morphometrical-statistical structure analysis of human striatum, pallidus and subthalamic nucleus. II. Globus pallidus. J. Hirnforsch., 1975, 16(5), 401-413.
247. Diamond, M.C.; Scheibel, A.B.; Murphy, G.M. Jr.; Harvey, T. On the brain of a scientist: Albert Einstein. Exp. Neurol., 1985, 88(1), 198-204.
248. Pakkenberg, B.; Gundersen, H.J. Total number of neurons and glial cells in human brain nuclei estimated by the dissector and the fractionator. J. Microsc., 1988, 150(Pt 1), 1-20.
249. Leuba, G.; Garey, L.J. Comparison of neuronal and glial numerical density in primary and secondary visual cortex of man. Exp. Brain Res., 1989, 77(1), 31-38.
250. Berne, R.M.; Rubio, R.; Curnish, R.R. Release of adenosine from ischemic brain: effect on cerebral vascular resistance and incorporation into cerebral adenine nucleotides. Circ. Res., 1974, 35, 262-271.
251. Bjerring, P.N.; Hauerberg, J.; Jørgensen, L.; Frederiksen, H.J.; Tofteng, F.; Hansen, B.A.; Larsen, F.S. Brain hypoxanthine concentration correlates to lactate/pyruvate ratio but not intracranial pressure in patients with acute liver failure. J. Hepatol., 2010, 53(6), 1054-1058.
252. Eells, J.T.; Spector, R. Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma. Neurochem. Res., 1983, 8(11), 1451-1457.
253. Hagberg, H.; Andersson, P.; Lacarewicz, J.; Jacobson, I.; Butcher, S.; Sandberg, M. Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J. Neurochem., 1987, 49(1), 227-231.
254. Melani, A.; De Micheli, E.; Pinna, G.; Alfieri, A.; Corte, L.D.; Pedata, F. Adenosine extracellular levels in human brain gliomas: an intraoperative microdialysis study. Neurosci. Lett., 2003, 346(1-2), 93-96.
255. Traut, T.W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem., 1994, 140(1), 1-22.
256. Mallol, J.; Bozal, J. Modification of 5'-nucleotidase activity by divalent cations and nucleotides. J. Neurochem., 1983, 40(5), 1205-1211.
257. James, S.; Richardson, P.J. Production of adenosine from extracellular ATP at the striatal cholinergic synapse. J. Neurochem., 1993, 60(1), 219-227.
258. Lai, K.M.; Wong, P.C. Metabolism of extracellular adenine nucleotides by cultured rat brain astrocytes. J. Neurochem., 1991, 57(5), 1510-1515.
259. Vetri, F.; Xu, H.; Mao, L.; Paisansathan, C.; Pelligrino, D.A. ATP hydrolysis pathways and their contributions to pial arteriolar dilation in rats. Am. J. Physiol. Heart Circ. Physiol., 2011, 301(4), 1369-1377.
260. Rudolphi, K.A.; Schubert, P.; Parkinson, F.E.; Fredholm, B.B. Adenosine and brain ischemia. Cerebrovasc. Brain Metab. Rev., 1992, 4(4), 346-369.
261. Klyuch, B.P.; Dale, N.; Wall, M.J. Deletion of ecto-5'-nucleotidase (CD73) reveals direct action potential-dependent adenosine release. J. Neurosci., 2012, 32(11), 3842-3847.
262. Pearce, W.J. Mechanisms of hypoxic cerebral vasodilatation. Pharmacol. Ther., 1995, 65(1), 75-91.
263. Pinto-Duarte, A.; Coelho, J.E.; Cunha, R.A.; Ribeiro, J.A.; Sebastião, A.M. Adenosine A2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. J. Neurochem., 2005, 93(3), 595-604.
264. Dunwiddie, T.V.; Diao, L.; Proctor, W.R. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J. Neurosci., 1997, 17(20), 7673-7682.
265. Glass, M.; Faull, R.L.; Dragunow, M. Localisation of the adenosine uptake site in the human brain: a comparison with the distribution of adenosine A1 receptors. Brain Res., 1996, 710(1-2), 79-91.
266. Boeck, C.R.; Kroth, E.H.; Bronzatto, M.J.; Vendite, D. Effect of the L-or D-aspartate on ecto-5'nucleotidase activity and on cellular viability in cultured neurons: participation of the adenosine A(2A) receptors. Amino Acids, 2007, 33(3), 439-444.
267. Richardson, P.J.; Brown, S.J.; Bailyes, E.M.; Luzio, J.P. Ectoenzymes control adenosine modulation of immunoisolated cholinergic synapses. Nature, 1987, 327(6119), 232-234.
268. Mazurkiewicz, D.; Saggerson, D. Changes in the activities of adenosine-metabolizing enzymes in six regions of the rat brain on chemical induction of hypothyroidism. Biochem. J., 1989, 261(2), 667-672.
269. Casadó, V.; Lluis, C.; Canela, E.; Franco, R.; Mallol, J. The distribution of A1 adenosine receptor and 5'-nucleotidase in pig brain cortex subcellular fractions. Neurochem. Res., 1992, 17(2), 129-139.
270. Frick, G.P.; Lowenstein, J.M. Vectorial production of adenosine by 5'-nucleotidase in the perfused rat heart. J. Biol. Chem., 1978, 253(4), 1240-1244.
271. Stanley, K.K.; Newby, A.C.; Luzio, J.P. What do ectoenzymes do? Trends Biochem. Sci., 1982, 7(4), 145-147.
272. Fleit, H.; Conklyn, M.; Stebbins, R.D.; Silber, R. Function of 5'-nucleotidase in the uptake of adenosine from AMP by human lymphocytes. J. Biol. Chem., 1975, 250(23), 8889-8892.
273. Pearson, J.D.; Carleton, J.S.; Gordon, J.L. Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smoothmuscle cells in culture. Biochem. J., 1980, 190(2), 421-429.
274. Amaral, D.G. The anatomical organization of the central nervous system. In: Principles of neural science; Kandel, E.R.; Schwartz, J.H.; Jessell, T.M., Eds.; McGraw-Hill Companies, Fourth Edition: New York, 2009, pp. 324-336.
275. Wang, X.; Lu, T.; Bendor, D.; Bartlett, E. Neural coding of temporal information in auditory thalamus and cortex. Neuroscience, 2008, 157(2), 484-494.
276. Nachev, P.; Kennard, C.; Husain, M. Functional role of the supplementary and pre-supplementary motor areas. Nat. Rev. Neurosci., 2008, 9(11), 856-869.
277. Tiesinga, P.; Fellous, J.M.; Sejnowski, T.J. Regulation of spike timing in visual cortical circuits. Nat. Rev. Neurosci., 2008, 9(2), 97-107.
278. Deco, G.; Rolls, E.T. Attention, short-term memory, and action selection: a unifying theory. Prog. Neurobiol., 2005, 76(4), 236-256.
279. Boison, D. Adenosine as a neuromodulator in neurological diseases. Curr. Opin. Pharmacol., 2008, 8(1), 2-7.
280. Merighi, S.; Mirandola, P.; Varani, K.; Gessi, S.; Leung, E.; Baraldi, P.G.; Tabrizi, M.A.; Borea, P.A. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol. Ther., 2003, 100(1), 31-48.
281. De Clercq, E. A 40-year journey in search of selective antiviral chemotherapy. Annu. Rev. Pharmacol. Toxicol., 2011, 51, 1-24.
282. Borst, P.; Balzarini, J.; Ono, N.; Reid, G.; de Vries, H.; Wielinga, P.; Wijnholds, J.; Zelcer, N. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res. 2004, 62(1), 1-7.
283. King, A.E.; Ackley, M.A.; Cass, C.E.; Young, J.D.; Baldwin, S.A. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol. Sci., 2006, 27(8), 416-425.
284. Headrick, J.P.; Peart, J.N.; Reichelt, M.E.; Haseler, L.J. Adenosine and its receptors in the heart: regulation, retaliation and adaptation. Biochim. Biophys. Acta, 2011, 1808(5), 1413-1428.
285. Samsel, M.; Dzierzbicka, K. Therapeutic potential of adenosine analogues and conjugates. Pharmacol. Rep., 2011, 63(3), 601-617.
286. Han, A.; Li, L.; Qing, K.; Qi, X.; Hou, L.; Luo, X.; Shi, S.; Ye, F. Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). Bioorg. Med. Chem. Lett., 2013, 23(5), 1310-1314.
287. Linker, R.A.; Kieseier, B.C.; Gold, R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol. Sci., 2008, 29(11), 558-565.
288. Leist, T.P.; Weissert, R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin. Neuropharmacol., 2011, 34(1), 28-35.
289. Chen, J.F.; Xu, K.; Petzer, J.P.; Staal, R.; Xu, Y.H.; Beilstein, M.; Sonsalla, P.K.; Castagnoli, K.; Castagnoli, N. Jr.; Schwarzschild, M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci., 2001, 21(10), RC143.
290. Hodgson, R.A.; Bedard, P.J.; Varty, G.B.; Kazdoba, T.M.; Di Paolo, T.; Grzelak, M.E.; Pond, A.J.; Hadjtahar, A.; Belanger, N.; Gregoire, L.; Dare, A.; Neustadt, B.R.; Stamford, A.W.; Hunter, J.C. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp. Neurol., 2010, 225(2), 384-390.
291. Kanda, T.; Jackson, M.J.; Smith, L.A.; Pearce, R.K.; Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol., 1998, 43(4), 507-513.
292. Kanda, T.; Jackson, M.J.; Smith, L.A.; Pearce, R.K.; Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol., 2000, 162(2), 321-327.
293. Blum, D.; Hourez, R.; Galas, M.C.; Popoli, P.; Schiffmann, S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol., 2003, 2(6), 366-374.
294. Chou, S.Y.; Lee, Y.C.; Chen, H.M.; Chiang, M.C.; Lai, H.L.; Chang, H.H.; Wu, Y.C.; Sun, C.N.; Chien, C.L.; Lin, Y.S.; Wang, S.C.; Tung, Y.Y.; Chang, C.; Chern, Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem., 2005, 93(2), 310-320.
295. Popoli, P.; Blum, D.; Martine, A.; Ledent, C.; Ceruti, S.; Abbracchio, M.P. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog. Neurobiol., 2007, 81(5-6), 331-348.
296. Hauser, R.A.; Cantillon, M.; Pourcher, E.; Micheli, F.; Mok, V.; Onofrj, M.; Huyck, S.; Wolski, K. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol., 2011, 10(3), 221-229.
297. Ferré, S.; Diamond, I.; Goldberg, S.R.; Yao, L.; Hourani, S.M.; Huang, Z.L.; Urade, Y.; Kitchen, I. Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. Prog. Neurobiol., 2007, 83(5), 332-347.
298. Brundege, J.M.; Williams, J.T. Increase in adenosine sensitivity in the nucleus accumbens following chronic morphine treatment. J. Neurophysiol., 2002, 87(3), 1369-1375.
299. Moreau, J.L.; Huber, G. Central adenosine A2A recetors: an overview. Brain Res. Rev., 1999, 31(1), 65-82.
300. Zylka, M.J. Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol. Med., 2011, 17(4), 188-196.
301. Elzein, E.; Zablocki, J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert. Opin. Investig. Drugs., 2008, 17(12), 1901-1910.
302. McGaraughty, S.; Cowart, M.; Jarvis, M.F.; Berman, R.F. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr. Top. Med. Chem., 2005, 5(1), 43-58.
303. Chen, J.; Rinaldo, L.; Lim, S.J.; Young, H.; Messing, R.O.; Choi, D.S. The type 1 equilibrative nucleoside transporter regulates anxiety-like behavior in mice. Genes Brain Behav., 2007, 6(8), 776-783.
304. Akhondzadeh, S.; Milajerdi, M.R.; Amini, H.; Tehrani-Doost, M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebocontrolled trial. Bipolar Disord., 2006, 8(5 Pt 1), 485-489.
305. Maemoto, T.; Tada, M.; Mihara, T.; Ueyama, N.; Matsuoka, H.; Harada, K.; Yamaji, T.; Shirakawa, K.; Kuroda, S.; Akahane, A.; Iwashita, A.; Matsuoka, N.; Mutoh, S. Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J. Pharmacol. Sci., 2004, 96(1), 42-52.
306. Akhondzadeh, S.; Shasavand, E.; Jamilian, H.; Shabestari, O.; Kamalipour, A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther., 2000, 25(2), 131-137.
307. Akhondzadeh, S.; Safarcherati, A.; Amini, H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(2), 253-259.
308. Lara, D.R.; Dall'Igna, O.P.; Ghisolfi, E.S.; Brunstein, M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(4), 617-629.
309. Boison, D.; Singer, P.; Shen, H.Y.; Feldon, J.; Yee, B.K. Adenosine hypothesis of schizophrenia-opportunities for pharmacotherapy. Neuropharmacology, 2012, 62(3), 1527-1543.
310. Boison, D. Adenosine Augmentation Therapy. In: Jasper's Basic Mechanisms of the Epilepsies [Internet]; Noebels, J.L.; Avoli, M.; Rogawski. M.A.; Olsen, R.W; Delgado-Escueta, A.V., Eds.; Bethesda (MD): National Center for Biotechnology Information (US), 2012; 4th edition; Available from: http://www.ncbi.nlm.nih.gov/books/NBK98157/
311. Etherington, L.A.; Patterson, G.E.; Meechan, L.; Boison, D.; Irving, A.J.; Dale, N.; Frenguelli, B.G. Astrocytic adenosine kinase regulates basal synaptic adenosine levels and seizure activity but not activity-dependent adenosine release in the hippocampus. Neuropharmacology, 2009, 56(2), 429-437.
312. Liang, C.S.; Yang, F.W.; Chiang, K.T.; Ho, P.S. Allopurinol for treatment-resistant schizophrenia and epilepsy: a case report. Pharmacopsychiatry, 2010, 43(6), 233-234.
313. Akula, K.K.; Dhir, A.; Kulkarni, S.K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy Res., 2008, 78(1), 60-70.
314. Rosim, F.E.; Persike, D.S.; Nehlig, A.; Amorim, R.P.; de Oliveira, D.M.; Fernandes, M.J. Differential neuroprotection by A(1) receptor activation and A(2A) receptor inhibition following pilocarpineinduced status epilepticus. Epilepsy Behav., 2011, 22(2), 207-213.
315. Erion, M.D.; Ugarkar, B.G.; Dare, J.; Castellino, A.J.; Fujitaki, J.M.; Dixon, R.; Appleman, J.R.; Wiesner, J.B. Design, synthesis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269. Nucleos. Nucleot., 1997, 16(7-9), 1013-1021.
316. Togha, M.; Akhondzadeh, S.; Motamedi, M.; Ahmadi, B.; Razeghi, S. Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. Arch. Med. Res., 2007, 38(3), 313-316.
317. Rother, M.; Erkinjuntti, T.; Roessner, M.; Kittner, B.; Marcusson, J.; Karlsson, I. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement. Geriatr. Cogn. Disord., 1998, 9(Suppl 1), 36-43.
318. Kittner, B.; Rossner, M.; Rother, M. Clinical trials in dementia with propentofylline. Ann. N. Y. Acad. Sci., 1997, 826, 307-316.
319. Cansev, M.; Ulus, I.H.; Wang, L.; Maher, T.J.; Wurtman, R.J. Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci. Res., 2008, 62(3), 206-209.
320. Deutsch, S.I.; Long, K.D.; Rosse, R.B.; Mastropaolo, J.; Eller, J. Hypothesized deficiency of guanine-based purines may contribute to abnormalities of neurodevelopment, neuromodulation, and neurotransmission in Lesch-Nyhan syndrome. Clin. Neuropharmacol., 2005, 28(1), 28-37.
321. Schmidt, A.P.; Böhmer, A.E.; Schallenberger, C.; Antunes, C.; Pereira, M.S.; Leke, R.; Wofchuk, S.T.; Elisabetsky, E.; Souza, D.O. Spinal mechanisms of antinociceptive action caused by guanosine in mice. Eur. J. Pharmacol., 2009, 613(1-3), 46-53.
322. Schmidt, A.P.; Lara, D.R.; de Faria Maraschin, J.; da Silveira Perla, A.; Souza, D.O. Guanosine and GMP prevent seizures induced by quinolinic acid in mice. Brain Res., 2000, 864(1), 40-43.
323. De Oliveira, D.L.; Horn, J.F.; Rodrigues, J.M.; Frizzo, M.E.; Moriguchi, E.; Souza, D.O.; Wofchuk, S. Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine. Brain Res., 2004, 1018(1), 48-54.
324. Vinadé, E.R.; Schmidt, A.P.; Frizzo, M.E.; Izquierdo, I.; Elisabetsky, E.; Souza, D.O. Chronically administered guanosine is anticonvulsant, amnesic and anxiolytic in mice. Brain Res., 2003, 977(1), 97-102.
325. Zhao, Q.; Marolewski, A.; Rusche, J.R.; Holmes, G.L. Effects of uridine
326. Zhao, Q.; Shatskikh, T.; Marolewski, A.; Rusche, J.R.; Holmes, G.L. Effects of uridine on kindling. Epilepsy Behav., 2008, 13(1), 47-51.
327. Honda, K.; Komoda, Y.; Nishida, S.; Nagasaki, H.; Higashi, A.; Uchizono, K.; Inoue, S. Uridine as an active component of sleeppromoting substance: its effects on nocturnal sleep in rats. Neurosci. Res., 1984, 1(4), 243-252.
328. Van der Beek, E.M.; Kamphuis, P. The potential role of nutritional components in the management of Alzheimer's Disease. Eur. J. Pharmacol., 2008, 585(1), 197-207.
329. Wurtman, R.J.; Cansev, M.; Sakamoto, T.; Ulus, I.H. Use of phosphatide precursors to promote synaptogenesis. Annu. Rev. Nutr., 2009, 29, 59-87.
330. Chang, R.; Algird, A.; Bau, C.; Rathbone, M.P.; Jiang, S. Neuroprotective effects of guanosine on stroke models in vitro and in vivo. Neurosci. Lett., 2008, 431(2), 101-105.
331. Shen, H.; Chen, G.J.; Harvey, B.K.; Bickford, P.C.; Wang, Y. Inosine reduces ischemic brain injury in rats. Stroke, 2005, 36(3), 654-659.
332. Markowitz, C.E.; Spitsin, S.; Zimmerman, V.; Jacobs, D.; Udupa, J.K.; Hooper, D.C.; Koprowski, H. The treatment of multiple sclerosis with inosine. J. Altern. Complement. Med., 2009, 15(6), 619-625.
333. Tort, A.B.; Mantese, C.E.; dos Anjos, G.M.; Dietrich, M.O.; Dall'Igna, O.P.; Souza, D.O.; Lara, D.R. Guanosine selectively inhibits locomotor stimulation induced by the NMDA antagonist dizocilpine. Behav. Brain Res., 2004, 154(2), 417-422.
334. Cansev, M. Uridine and cytidine in the brain: Their transport and utilization. Brain Res. Rev., 2006, 52(2), 389-397.
335. Connolly, G.P.; Duley, J.A. Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol. Sci., 1999, 20(5), 218-225.
336. Pesi, R.; Micheli, V.; Jacomelli, G.; Peruzzi, L.; Camici, M.; Garcia-Gil, M.; Allegrini, S.; Tozzi, M.G. Cytosolic 5'-nucleotidase hyperactivity in erythrocytes of Lesch-Nyhan syndrome patients. Neuroreport, 2000, 11(9), 1827-1831.
337. Pesi, R.; Camici, M.; Micheli, V.; Notarantonio, L.; Jacomelli, G.; Tozzi, M.G. Identification of the nucleotidase responsible for the AMP hydrolysing hyperactivity associated with neurological and developmental disorders. Neurochem. Res., 2008, 33(1), 59-65.
338. Page, T.; Yu, A.; Fontanesi, J.; Nyhan, W.L. Developmental disorder associated with increased cellular nucleotidase activity. Proc. Natl. Acad. Sci. U.S.A., 1997, 94(21), 11601-11606.
339. Busnello, J.V.; Oses, J.P.; da Silva, R.S.; Feier, G.; Barichello, T.; Quevedo, J.; Böhmer, A.E.; Kapczinski, F.; Souza, D.O.; Sarkis, J.J.; Portela, L.V. Peripheral nucleotide hydrolysis in rats submitted to a model of electroconvulsive therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2008, 32(8), 1829-1833.
340. Lara, D.R.; Vianna, M.R.; de Paris, F.; Quevedo, J.; Oses, J.P.; Battastini, A.M.; Sarkis, J.J.; Souza, D.O. Chronic treatment with clozapine, but not haloperidol, increases striatal ecto-5'-nucleotidase activity in rats. Neuropsychobiology, 2001, 44(2), 99-102.
341. Girardi, E.; Perez Raffo, G.; Rodriguez de Lores Arnaiz, G. A study of 5'-nucleotidase activity in subcellular fractions of rat cerebellum after the administration of the convulsant 3-mercaptopropionic acid. Mol. Chem. Neuropathol., 1989, 11(2), 65-75.
342. Cognato, G. de P.; Bruno, A.N.; da Silva, R.S.; Bogo, M.R.; Sarkis, J.J.; Bonan, C.D. Antiepileptic drugs prevent changes induced by pilocarpine model of epilepsy in brain ecto-nucleotidases. Neurochem. Res., 2007, 32(6), 1046-1055.
343. Schoen, S.W.; Ebert, U.; Löscher, W. 5'-Nucleotidase activity of mossy fibers in the dentate gyrus of normal and epileptic rats. Neuroscience, 1999, 93(2), 519-526.
344. Li, X.; Zhou, T.; Zhi, X.; Zhao, F.; Yin, L.; Zhou, P. Effect of hypoxia/reoxygenation on CD73 (ecto-5'-nucleotidase) in mouse microvessel endothelial cell lines. Microvasc. Res., 2006, 72(1-2), 48-53.
345. Sweeney, M.I. Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Neurosci. Biobehav. Rev., 1997, 21(2), 207-217.
346. Meijer, P.; Wouters, C.W.; van den Broek, P.H.; de Rooij, M.; Scheffer, G.J.; Smits, P.; Rongen, G.A. Upregulation of ecto-5'-nucleotidase by rosuvastatin increases the vasodilator response to ischemia. Hypertension, 2010, 56(4), 722-727.
347. Nedeljkovic, N.; Bjelobaba, I.; Subasic, S.; Lavrnja, I.; Pekovic, S.; Stojkov, D.; Vjestica, A.; Rakic, L.; Stojiljkovic, M. Up-regulation of ectonucleotidase activity after cortical stab injury in rats. Cell Biol. Int., 2006, 30(6), 541-546.
348. Bjelobaba, I.; Parabucki, A.; Lavrnja, I.; Stojkov, D.; Dacic, S.; Pekovic, S.; Rakic, L.; Stojiljkovic, M.; Nedeljkovic, N. Dynamic changes in the expression pattern of ecto-5'-nucleotidase in the rat model of cortical stab injury. J. Neurosci. Res., 2011, 89(6), 862-873.
349. Cognato, G. de P.; Bonan, C.D. Ectonucleotidases and Epilepsy. Open Neurosci. J., 2010, 4, 44-52.
350. Szentmiklósi, A.J.; Cseppento, A.; Harmati, G.; Nánási, P.P. Novel trends in the treatment of cardiovascular disorders: site-and eventselective adenosinergic drugs. Curr. Med. Chem., 2011, 18(8), 1164-1187.
351. Brisevac, D.; Bjelobaba, I.; Bajic, A.; Clarner, T.; Stojiljkovic, M.; Beyer, C.; Andjus, P.; Kipp, M.; Nedeljkovic, N. Regulation of ecto-5'-nucleotidase (CD73) in cultured cortical astrocytes by different inflammatory factors. Neurochem. Int., 2012, 61(5), 681-688.
352. Muzzi, M.; Blasi, F.; Masi, A.; Coppi, E.; Traini, C.; Felici, R.; Pittelli, M.; Cavone, L.; Pugliese, A.M.; Moroni, F.; Chiarugi, A. Neurological basis of AMP-dependent thermoregulation and its relevance to central and peripheral hyperthermia. J. Cereb. Blood Flow Metab., 2013, 33(2), 183-190.
353. Cielak, M.; Komoszyski, M. The role of ecto-purines in inflammation leading to demyelination-new means for therapies against multiple sclerosis. Neurol. Neurochir. Pol., 2011, 45(5), 489-499.
354. Niemelä, J.; Ifergan, I.; Yegutkin, G.G.; Jalkanen, S.; Prat, A.; Airas, L. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur. J. Immunol., 2008, 38(10), 2718-2726.
355. Airas, L.; Niemelä, J.; Yegutkin, G.; Jalkanen, S. Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine. Ann. N. Y. Acad. Sci., 2007, 1110, 641-648.
356. Lewin, E.; Bleck, V. Effect of inosine on seizures induced with pentylenetetrazole, bicuculline, or picrotoxin. Epilepsia, 1985, 26(3), 258-261.
357. Lara, D.R.; Schmidt, A.P.; Frizzo, M.E.; Burgos, J.S.; Ramírez, G.; Souza, D.O. Effect of orally administered guanosine on seizures and death induced by glutamatergic agents. Brain Res., 2001, 912(2), 176-180.
358. Boison, D.; Stewart, K.A. Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation. Biochem. Pharmacol., 2009, 78(12), 1428-1437.
359. Nicolaidis, R.; Bruno, A.N.; Sarkis, J.J.; Souza, D.O. Increase of adenine nucleotide hydrolysis in rat hippocampal slices after seizures induced by quinolinic acid. Neurochem. Res., 2005, 30(3), 385-390.
360. Soares, F.A.; Schmidt, A.P.; Farina, M.; Frizzo, M.E.; Tavares, R.G.; Portela, L.V.; Lara, D.R.; Souza, D.O. Anticonvulsant effect of GMP depends on its conversion to guanosine. Brain Res., 2004, 1005(1-2), 182-186.
361. Sowa, N.A.; Voss, M.K.; Zylka, M.J. Recombinant ecto-5'-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation. Mol. Pain, 2010, 6, 20.
362. Street, S.E.; Walsh, P.L.; Sowa, N.A.; Taylor-Blake, B.; Guillot, T.S.; Vihko, P.; Wightman, R.M.; Zylka, M.J. PAP and NT5E inhibit nociceptive neurotransmission by rapidly hydrolyzing nucleotides to adenosine. Mol. Pain, 2011, 7, 80.
363. Stagg, J.; Beavis, P.A.; Divisekera, U.; Liu, M.C.; Möller, A.; Darcy, P.K.; Smyth, M.J. CD73-deficient mice are resistant to carcinogenesis. Cancer Res., 2012, 72(9), 2190-2196.
364. Kumasaka, T.; Matsuoka, I.; Mashiko, H.; Niwa, S.; Kimura, J. Inactivation of membrane surface ecto-5'-nucleotidase by sodium nitroprusside in C6 glioma cells. J. Pharmacol. Sci., 2011, 117(1), 45-53.
365. Torres, M.; Pintor, J.; Miras-Portugal, M.T. Presence of ectonucleotidases in cultured chromaffin cells: hydrolysis of extracellular adenine nucleotides. Arch. Biochem. Biophys., 1990, 279(1), 37-44.
366. Baqi, Y.; Lee, S.Y.; Iqbal, J.; Ripphausen, P.; Lehr, A.; Scheiff, A.B.; Zimmermann, H.; Bajorath, J.; Müller, C.E. Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J. Med. Chem., 2010, 53(5), 2076-2086.
367. Braganhol, E.; Tamajusuku, A.S.; Bernardi, A.; Wink, M.R.; Battastini, A.M. Ecto-5'-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochim. Biophys. Acta, 2007, 1770(9), 1352-1359.
368. Zhang, B. CD73: a novel target for cancer immunotherapy. Cancer Res., 2010, 70(16), 6407-6411.
369. Braganhol, E.; Zamin, L.L.; Canedo, A.D.; Horn, F.; Tamajusuku, A.S.; Wink, M.R.; Salbego, C.; Battastini, A.M. Antiproliferative effect of quercetin in the human U138MG glioma cell line. Anticancer Drugs, 2006, 17(6), 663-671.
370. Spychala, J. Tumor-promoting functions of adenosine. Pharmacol. Ther., 2000, 87(2-3), 161-173.
371. Wang, H.; Lee, S.; Nigro, C.L.; Lattanzio, L.; Merlano, M.; Monteverde, M.; Matin, R.; Purdie, K.; Mladkova, N.; Bergamaschi, D.; Harwood, C.; Syed, N.; Szlosarek, P.; Briasoulis, E.; McHugh, A.; Thompson, A.; Evans, A.; Leigh, I.; Fleming, C.; Inman, G.J.; Hatzimichael, E.; Proby, C.; Crook, T. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br. J. Cancer, 2012, 106(8), 1446-1452.
372. Galmarini, C.M.; Mackey, J.R.; Dumontet, C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol., 2002, 3(7), 415-424.
373. Zhang, G.; Franklin, P.H.; Murray, T.F. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J. Pharmacol. Exp. Ther., 1993, 264(3), 1415-1424.
374. Kanfer, J.N.; Hattori, H.; Orihel, D. Reduced phospholipase D activity in brain tissue samples from Alzheimer's disease patients. Ann. Neurol., 1986, 20(2), 265-267.